Literature DB >> 3186723

Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein.

E Seto1, T S Yen, B M Peterlin, J H Ou.   

Abstract

Human immunodeficiency virus 1 has been implicated as the main etiologic agent of the acquired immunodeficiency syndrome. However, other infectious agents may accelerate the progression of this disease. In particular, hepatitis B virus has been suggested as one such cofactor. Therefore, we have investigated the effects of hepatitis B virus gene products on expression of the human immunodeficiency virus I in transient transfection studies of Jurkat lymphoblastic T cells, using as reporter the chloramphenicol acetyltransferase gene coupled to the long terminal repeat of human immunodeficiency virus I. As measured by the amount of chloramphenicol acetyltransferase activity, gene expression directed by the human immunodeficiency virus I long terminal repeat increased approximately 10-fold in response to the hepatitis B virus X protein. This trans-activation by the X protein is multiplicative with the effect of phorbol esters and can be accounted for by an increase in the steady-state level of chloramphenicol acetyltransferase mRNA. Analysis of deletion and clustered point mutants in the long terminal repeat indicated that the X protein exerts its effect through multiple cis-acting sites. These results provide a possible molecular basis for the association of hepatitis B virus and the acquired immunodeficiency syndrome and confirm that the X protein is a transcriptional transactivator.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3186723      PMCID: PMC282414          DOI: 10.1073/pnas.85.21.8286

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Hepatitis B surface antigen could harbour the infective agent of AIDS.

Authors:  M I McDonald; J D Hamilton; D T Durack
Journal:  Lancet       Date:  1983-10-15       Impact factor: 79.321

2.  Role of hepatitis B virus in acquired immunodeficiency syndrome.

Authors:  R T Ravenholt
Journal:  Lancet       Date:  1983-10-15       Impact factor: 79.321

3.  Retrovirus resembling HTLV in macrophages of patients with AIDS.

Authors:  F Gyorkey; J L Melnick; J G Sinkovics; P Gyorkey
Journal:  Lancet       Date:  1985-01-12       Impact factor: 79.321

4.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

Authors:  D A Melton; P A Krieg; M R Rebagliati; T Maniatis; K Zinn; M R Green
Journal:  Nucleic Acids Res       Date:  1984-09-25       Impact factor: 16.971

5.  No increased incidence of AIDS in recipients of hepatitis B vaccine.

Authors:  J A Golden
Journal:  N Engl J Med       Date:  1983-05-12       Impact factor: 91.245

6.  Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat.

Authors:  J Sodroski; C Rosen; F Wong-Staal; S Z Salahuddin; M Popovic; S Arya; R C Gallo; W A Haseltine
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

7.  Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes.

Authors:  D Klatzmann; F Barré-Sinoussi; M T Nugeyre; C Danquet; E Vilmer; C Griscelli; F Brun-Veziret; C Rouzioux; J C Gluckman; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

8.  Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells.

Authors:  G J Nabel; S A Rice; D M Knipe; D Baltimore
Journal:  Science       Date:  1988-03-11       Impact factor: 47.728

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.

Authors:  H Dinter; R Chiu; M Imagawa; M Karin; K A Jones
Journal:  EMBO J       Date:  1987-12-20       Impact factor: 11.598

View more
  81 in total

1.  Different regions of hepatitis B virus X protein are required for enhancement of bZip-mediated transactivation versus transrepression.

Authors:  S Barnabas; O M Andrisani
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  The cloning of 3'-truncated preS/S gene from HBV genomic DNA and its expression in transgenic mice.

Authors:  Yi-Ping Hu; Yu-Cheng Yao; Jian-Xiu Li; Xin-Min Wang; Hong Li; Zhong-Hua Wang; Zhang-Heng Lei
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

3.  Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis.

Authors:  X W Wang
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

4.  Alternate translation initiation on hepatitis B virus X mRNA produces multiple polypeptides that differentially transactivate class II and III promoters.

Authors:  L Kwee; R Lucito; B Aufiero; R J Schneider
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus.

Authors:  K A Stellrecht; K Sperber; B G Pogo
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Mutational analysis of enhancer domains responsive to trans-activation by the X gene of human hepatitis B virus.

Authors:  G Goodarzi; H Ohno; R Adams; A Darabi; A Tewari; M Watabe; K Watabe
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls.

Authors:  J Benn; R J Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  Infection with the intracellular protozoan parasite Theileria parva induces constitutively high levels of NF-kappa B in bovine T lymphocytes.

Authors:  V Ivanov; B Stein; I Baumann; D A Dobbelaere; P Herrlich; R O Williams
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

9.  Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.

Authors:  John Idoko; Seema Meloni; Mohammed Muazu; Ladep Nimzing; Bitrus Badung; Claudia Hawkins; Jean-Louis Sankalé; Ernest Ekong; Robert Murphy; Phyllis Kanki; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

10.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.